Aussie needle-free RSV vax coming

The United States National Institutes of Health (NIH) has granted Aussie biotech Vaxxas the licence to a vaccine antigen candidate (DS2), to protect against Respiratory Syncytial Virus (RSV).

Vaxxas' worldwide licence from the NIH enables the company to develop the first needle-free, room-temperature stable RSV vaccine to enter clinical studies.

The DS2 RSV vaccine antigen candidate was developed by scientists at the NIH's Vaccine Research Centre and the National Institute of Allergy and Infectious Diseases.

"Published preclinical results show the potential immunogenic advantages of this antigen candidate as the basis for an RSV vaccine to provide robust and durable protection," Vaxxas CEO David Hoey said.